Business Context and Reporting Period
Company: Novavax, Inc. (NVAX)
Filing Type: Form 8-K (Current Report)
Date of Report: October 17, 2025
Event: Entry into material definitive agreements with AstraZeneca Pharmaceuticals LP regarding the assignment of the Company's lease at 700 Quince Orchard Road, Gaithersburg, MD, and the sale of adjacent land and assets. The Company has relocated its corporate headquarters to 21 Firstfield Road, Gaithersburg, MD.
Key Financial Metrics and Transaction Values
- Total Proceeds from AstraZeneca: $59.8 million aggregate payable.
- Payment Schedule:
- $20.0 million (Parcel Purchase): Expected in Q4 2025.
- $15.0 million (Lease Assignment Fee): Due upon execution of landlord consent (post-January 5, 2026).
- $24.8 million (Asset Purchase): $4.0 million deposit paid; remainder due on closing (expected on or before January 5, 2026).
- Expected Non-Cash Charges (Q3 2025): Total estimated between $125 million and $127 million.
- Impairment Charge: $96 million to $98 million (related to the facility transactions, including write-offs of right-of-use assets, property, equipment, and intangibles, partially offset by a gain on land sale).
- Debt Extinguishment Charge: $29 million (related to the 5.00% Convertible Senior Notes due 2027).
- Cash Impact: The impairment charge is non-cash and is not expected to result in current or future cash expenditures.
Material Changes and Transaction Details
The filing details three primary agreements executed on October 17, 2025:
- Assignment and Assumption of Lease: Novavax assigns its lease for approximately 171,239 square feet (term through December 2036) to AstraZeneca. AstraZeneca assumes all tenant rights and obligations effective January 5, 2026. Novavax remains responsible for base rent from January 5, 2026, through June 30, 2026.
- Parcel Purchase Agreement: Sale of approximately 9.7 acres of land in Gaithersburg, MD, for $20.0 million. Closing expected in Q4 2025.
- Asset Purchase Agreement: Sale of equipment, warranties, licenses, and permits located at the premises for $24.8 million. Closing expected on or before January 5, 2026.
Outlook, Risks, and Management Commentary
Management Commentary: The Company expects to recognize the impairment charges in the third quarter of 2025. The transactions are part of a strategic move to consolidate operations at the new headquarters.
Risks and Uncertainties: The filing includes standard forward-looking statement disclaimers. Specific risks cited include:
- Regulatory authorization delays for COVID-19 vaccines (including JN.1 protein-based variants).
- Antigenic drift or shift in SARS-CoV-2.
- Supply chain constraints and raw material scarcity.
- Dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling.
- Manufacturing, distribution, or export delays.
Investor Verification Checklist
- Verify the exact timing of the $20.0 million land sale closing in Q4 2025.
- Confirm the final amount of the Q3 2025 impairment charge once the financial statements are released (currently estimated at $96M-$98M).
- Monitor the status of the Landlord's written consent required for the lease assignment to become effective on January 5, 2026.
- Review the impact of the $29 million debt extinguishment charge on the Company's remaining capital structure.
- Assess the operational transition timeline for the new headquarters at 21 Firstfield Road.